On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne muscular dystrophy. Research & Clinical Trial Webinars,Webinars 4 years ago You may also like 02:15:11 PPMD’s Duchenne Early Intervention Symposium 7 hours ago Webinars newborn screening 01:08:05 Webinar: Solid Biosciences – Update on Gene Therapy Candidate SGT-003 2 weeks ago Research & Clinical Trial Webinars,Webinars gene therapy,sgt-003,solid biosciences 58:14 Webinar: Sevasemten – CANYON Trial Topline Results 3 months ago Research & Clinical Trial Webinars,Webinars edg-5506,edgewise 1:01:40 Webinar: RGX-202 – AFFINITY DUCHENNE Pivotal Program and Functional Data 4 months ago Research & Clinical Trial Webinars,Webinars gene therapy,RGX-202 51:49 Webinar: INSPIRE DUCHENNE Clinical Trial Update and Study Expansion 4 months ago Research & Clinical Trial Webinars,Webinars sgt-003,solid biosciences 56:19 Webinar: Exploring Muscle Regeneration – A New Approach with Satellos 4 months ago Research & Clinical Trial Webinars,Webinars 44:01 World Muscle Society 2024: CIFFREO Data Discussion with Pfizer 5 months ago Research & Clinical Trial Webinars,Webinars fordadistrogene movaparvovec,pfizer 59:49 Webinar: SHIELD DMD – A Bone Health Study in Duchenne 5 months ago Research & Clinical Trial Webinars,Webinars satralizumab 123…25»Page 1 of 25